Table 1.
Demographic and CSF data obtained at baseline of AD and LLD patients and controls.
| LLD (n = 48) (mean ±SD) | AD patients (n = 154) (mean ±SD) | Controls (n = 58) (mean ±SD) | |||
|---|---|---|---|---|---|
| Age (years) | 70.98 ± 3.26 | 71.99 ± 4.01 | 67.89 ± 4.95 | ||
| Sex | 19M 29F | 71M 83F | 28M 30F | ||
| T-tau (pg/mL) | 205.42 ± 83.21* | 676.59 ± 373.53◦ | 252.89 ± 43.26 | ||
| P-tau (pg/mL) | 33.46 ± 8.56* | 86.67 ± 51.28◦ | 32.75 ± 5.21 | ||
| Aβ42 (pg/mL) | 837.33 ± 194.96* | 306.33 ± 105.69◦ | 921.96 ± 69.55 | ||
| Baseline | Follow-up | Baseline | Follow-up | ||
| MMSE | 20.91 ± 3.27# | 24.35 ± 2.75* | 20.20 ± 2.84◦ | 17.06 ± 3.28 | 29.08 ± 0.90 |
| PHQ-9 | 17.58 ± 2.21 | 8.75 ± 1.83* | 17.01 ± 2.41 | 13.5 ± 3.34 | NA |
MMSE and PHQ-9 data of AD and LLD patients obtained at baseline and follow-up.
*
LLD vs. AD, p < 0.001;
◦
AD vs. Controls, p < 0.001;
#
LLD vs. Controls, p < 0.001.
F, female; M, male; MMSE; Mini Mental State Examination; PHQ-9, Patient Health Questionnaire 9; T-tau, total tau proteins; P-tau, phosphorylated tau proteins; Aβ42, beta amyloid 1-42; NA, not applicable.